Stylus Medicine
Latest round
- Series A
Last raised
- May 2025
Total raised
- $35M
Investors
- 5
About Stylus Medicine
Founded in 2022, Stylus Medicine focuses on developing in vivo genetic medicines.052 mn, with the most recent deal dated June 10, 2024. The company has not undergone any known pivots or changes in business operations.Stylus Medicine specializes in developing innovative in vivo genetic medicines, particularly focusing on engineered recombinases that facilitate the precise introduction of therapeutic payloads into the human genome. Their core product offerings center around in vivo CAR-T therapies, leveraging a cell-targeted lipid nanoparticle (LNP) delivery system to directly target immune cells within the body. This technology aims to solve critical healthcare challenges associated with treating various conditions, including oncology and autoimmune diseases, by providing precise, durable therapeutic effects. The company’s solutions are designed for a broad range of applications in the biopharmaceutical sector, targeting markets in North America, Europe, and parts of Asia, with an emphasis on accessibility and patient-centric treatment paradigms.Stylus Medicine's revenue model revolves around partnerships and collaborations within the biopharmaceutical ecosystem, engaging in agreements that facilitate the development and distribution of their genetic therapies. Revenue streams include collaborative research and development agreements and licensing deals with larger pharmaceutical entities seeking to utilize Stylus's proprietary technologies. The company’s flagship products, particularly their in vivo CAR-T therapies, are expected to generate revenue through direct partnerships with healthcare providers and research institutions focused on innovative cancer treatments. Pricing structures may vary based on the nature of the agreements, typically involving milestone payments, royalties, or service fees associated with the delivery of therapeutic solutions.Stylus Medicine plans to expand its product offerings by launching new in vivo CAR-T therapies, although specific release dates have not been disclosed. The company is targeting geographic expansion into several markets in Europe and Asia by the end of 2025.
Who invested in Stylus Medicine
5 investors across 1 round
See all investors in Stylus Medicine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 13, 2025
Amount
$35M
Investors
Questions about Stylus Medicine
Who invested in Stylus Medicine?
Stylus Medicine has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Stylus Medicine raised?
Stylus Medicine has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Stylus Medicine last raise money?
Stylus Medicine's most recent round on record is a Series A, in May 2025.
What does Stylus Medicine do?
Founded in 2022, Stylus Medicine focuses on developing in vivo genetic medicines.
Where is Stylus Medicine headquartered?
Stylus Medicine is headquartered in Cambridge, US.
Which VCs invest in companies like Stylus Medicine?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Stylus Medicine's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Stylus Medicine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.